Treatment of immune thrombocytopenia in Australian adults: A multicenter retrospective observational study
CONCLUSION: A wide range of "second-line" agents were used across centers with variable response rates and side effect profiles. Findings suggest greater effectiveness of rituximab and TPO-A, supporting their use earlier in the treatment course of patients with ITP across Australia.PMID:36186101 | PMC:PMC9483174 | DOI:10.1002/rth2.12792 (Source: Thrombosis and Haemostasis)
Source: Thrombosis and Haemostasis - October 3, 2022 Category: Hematology Authors: Adam Rosenberg Catelyn Cashion Fariya Ali Harini Haran Raaj K Biswas Vivien Chen Helen Crowther Jennifer Curnow Elyssa Deakin Chee-Wee Tan Yi Ling Tan Andrew Vanlint Christopher M Ward Robert Bird David J Rabbolini Source Type: research

Thromboelastography and thrombin generation assessments for pediatric severe hemophilia A patients are highly variable and not predictive of clinical phenotypes
CONCLUSIONS: In vitro hemostatic assay results of samples containing platelets showed concordance. Assay results were not predictive of FVIII requirements or correlated with other clinical parameters. SHA patient heterogeneity is influenced by factors other than baseline hemostatic activity.PMID:36186102 | PMC:PMC9511091 | DOI:10.1002/rth2.12800 (Source: Thrombosis and Haemostasis)
Source: Thrombosis and Haemostasis - October 3, 2022 Category: Hematology Authors: Natalie Mathews Fred G Pluthero Margaret L Rand Ann Marie Stain Manuel Carcao Victor S Blanchette Walter H A Kahr Source Type: research

Standardization of D-dimer reporting in the COVID-19 era
Res Pract Thromb Haemost. 2022 Sep 20;6(6):e12772. doi: 10.1002/rth2.12772. eCollection 2022 Aug.NO ABSTRACTPMID:36186103 | PMC:PMC9487443 | DOI:10.1002/rth2.12772 (Source: Thrombosis and Haemostasis)
Source: Thrombosis and Haemostasis - October 3, 2022 Category: Hematology Authors: Litao Zhang Zhenlu Zhang Source Type: research

Challenges and knowledge gaps facing hemophilia carriers today: Perspectives from patients and health care providers
Res Pract Thromb Haemost. 2022 Sep 20;6(6):e12783. doi: 10.1002/rth2.12783. eCollection 2022 Aug.ABSTRACTBACKGROUND: Hemophilia carriers experience abnormal bleeding symptoms; however, a lack of awareness about this topic coupled with additional knowledge gaps and barriers leads to suboptimal care for this population.OBJECTIVE: The primary objective was to describe the current knowledge gaps and challenges from the perspective of both hemophilia carriers and their health care providers.METHODS: We carried out a mixed methods descriptive study with two population groups between September and December 2020. The hemophilia ca...
Source: Thrombosis and Haemostasis - October 3, 2022 Category: Hematology Authors: Megan Chaigneau Monique Botros Julie Grabell Wilma Hopman Paula James Source Type: research

Anticoagulation stewardship: Descriptive analysis of a novel approach to appropriate anticoagulant prescription
CONCLUSION: Inpatient anticoagulant prescriptions were optimized following recommendations by the ASP team. The most frequent types of prescription changes concerned dose adjustments and drug interactions. Further research is required to assess the effect of an ASP on clinical outcomes.PMID:36186105 | PMC:PMC9510439 | DOI:10.1002/rth2.12758 (Source: Thrombosis and Haemostasis)
Source: Thrombosis and Haemostasis - October 3, 2022 Category: Hematology Authors: Maral Koolian Daniel Wiseman Helen Mantzanis Nikki Kampouris Ryan S Kerzner Susan R Kahn Source Type: research

Alteplase or tenecteplase for thrombolysis in ischemic stroke: An illustrated review
Res Pract Thromb Haemost. 2022 Sep 20;6(6):e12795. doi: 10.1002/rth2.12795. eCollection 2022 Aug.ABSTRACTIntravenous thrombolysis is a standard of care treatment for patients with acute ischemic stroke. Tissue plasminogen activator (tPA) has been the main thrombolytic agent used since the publication of the seminal National Institutes of Neurological Disorders and Stroke trial in 1995. There is now mounting evidence to support the routine use of Tenecteplase (TNK) to treat acute ischemic stroke. TNK is a genetically modified tPA with higher fibrin specificity, longer half-life, and reduced systemic coagulopathy. In this il...
Source: Thrombosis and Haemostasis - October 3, 2022 Category: Hematology Authors: Annie Zhu Phavalan Rajendram Eric Tseng Shelagh B Coutts Amy Y X Yu Source Type: research

Desmopressin testing in von Willebrand disease: Lowering the burden
CONCLUSION: Desmopressin testing is not needed when lowest historical VWF:Act is 0.30 IU/ml or greater. In patients with Type 1 VWD who require testing, measurements after T1 are often not needed. In patients with Type 2 VWD who require testing, we advise performing T1 and T4 measurements.PMID:36186107 | PMC:PMC9512764 | DOI:10.1002/rth2.12784 (Source: Thrombosis and Haemostasis)
Source: Thrombosis and Haemostasis - October 3, 2022 Category: Hematology Authors: Jessica M Heijdra Ferdows Atiq Wala Al Arashi Quincy Kieboom Esmee Wuijster Karina Meijer Marieke J H A Kruip Frank W G Leebeek Marjon H Cnossen OPTI ‐CLOT Study Group Source Type: research

Treatment of immune thrombocytopenia in Australian adults: A multicenter retrospective observational study
CONCLUSION: A wide range of "second-line" agents were used across centers with variable response rates and side effect profiles. Findings suggest greater effectiveness of rituximab and TPO-A, supporting their use earlier in the treatment course of patients with ITP across Australia.PMID:36186101 | PMC:PMC9483174 | DOI:10.1002/rth2.12792 (Source: Thrombosis and Haemostasis)
Source: Thrombosis and Haemostasis - October 3, 2022 Category: Hematology Authors: Adam Rosenberg Catelyn Cashion Fariya Ali Harini Haran Raaj K Biswas Vivien Chen Helen Crowther Jennifer Curnow Elyssa Deakin Chee-Wee Tan Yi Ling Tan Andrew Vanlint Christopher M Ward Robert Bird David J Rabbolini Source Type: research

Thromboelastography and thrombin generation assessments for pediatric severe hemophilia A patients are highly variable and not predictive of clinical phenotypes
CONCLUSIONS: In vitro hemostatic assay results of samples containing platelets showed concordance. Assay results were not predictive of FVIII requirements or correlated with other clinical parameters. SHA patient heterogeneity is influenced by factors other than baseline hemostatic activity.PMID:36186102 | PMC:PMC9511091 | DOI:10.1002/rth2.12800 (Source: Thrombosis and Haemostasis)
Source: Thrombosis and Haemostasis - October 3, 2022 Category: Hematology Authors: Natalie Mathews Fred G Pluthero Margaret L Rand Ann Marie Stain Manuel Carcao Victor S Blanchette Walter H A Kahr Source Type: research

Standardization of D-dimer reporting in the COVID-19 era
Res Pract Thromb Haemost. 2022 Sep 20;6(6):e12772. doi: 10.1002/rth2.12772. eCollection 2022 Aug.NO ABSTRACTPMID:36186103 | PMC:PMC9487443 | DOI:10.1002/rth2.12772 (Source: Thrombosis and Haemostasis)
Source: Thrombosis and Haemostasis - October 3, 2022 Category: Hematology Authors: Litao Zhang Zhenlu Zhang Source Type: research

Challenges and knowledge gaps facing hemophilia carriers today: Perspectives from patients and health care providers
Res Pract Thromb Haemost. 2022 Sep 20;6(6):e12783. doi: 10.1002/rth2.12783. eCollection 2022 Aug.ABSTRACTBACKGROUND: Hemophilia carriers experience abnormal bleeding symptoms; however, a lack of awareness about this topic coupled with additional knowledge gaps and barriers leads to suboptimal care for this population.OBJECTIVE: The primary objective was to describe the current knowledge gaps and challenges from the perspective of both hemophilia carriers and their health care providers.METHODS: We carried out a mixed methods descriptive study with two population groups between September and December 2020. The hemophilia ca...
Source: Thrombosis and Haemostasis - October 3, 2022 Category: Hematology Authors: Megan Chaigneau Monique Botros Julie Grabell Wilma Hopman Paula James Source Type: research

Anticoagulation stewardship: Descriptive analysis of a novel approach to appropriate anticoagulant prescription
CONCLUSION: Inpatient anticoagulant prescriptions were optimized following recommendations by the ASP team. The most frequent types of prescription changes concerned dose adjustments and drug interactions. Further research is required to assess the effect of an ASP on clinical outcomes.PMID:36186105 | PMC:PMC9510439 | DOI:10.1002/rth2.12758 (Source: Thrombosis and Haemostasis)
Source: Thrombosis and Haemostasis - October 3, 2022 Category: Hematology Authors: Maral Koolian Daniel Wiseman Helen Mantzanis Nikki Kampouris Ryan S Kerzner Susan R Kahn Source Type: research

Alteplase or tenecteplase for thrombolysis in ischemic stroke: An illustrated review
Res Pract Thromb Haemost. 2022 Sep 20;6(6):e12795. doi: 10.1002/rth2.12795. eCollection 2022 Aug.ABSTRACTIntravenous thrombolysis is a standard of care treatment for patients with acute ischemic stroke. Tissue plasminogen activator (tPA) has been the main thrombolytic agent used since the publication of the seminal National Institutes of Neurological Disorders and Stroke trial in 1995. There is now mounting evidence to support the routine use of Tenecteplase (TNK) to treat acute ischemic stroke. TNK is a genetically modified tPA with higher fibrin specificity, longer half-life, and reduced systemic coagulopathy. In this il...
Source: Thrombosis and Haemostasis - October 3, 2022 Category: Hematology Authors: Annie Zhu Phavalan Rajendram Eric Tseng Shelagh B Coutts Amy Y X Yu Source Type: research

Desmopressin testing in von Willebrand disease: Lowering the burden
CONCLUSION: Desmopressin testing is not needed when lowest historical VWF:Act is 0.30 IU/ml or greater. In patients with Type 1 VWD who require testing, measurements after T1 are often not needed. In patients with Type 2 VWD who require testing, we advise performing T1 and T4 measurements.PMID:36186107 | PMC:PMC9512764 | DOI:10.1002/rth2.12784 (Source: Thrombosis and Haemostasis)
Source: Thrombosis and Haemostasis - October 3, 2022 Category: Hematology Authors: Jessica M Heijdra Ferdows Atiq Wala Al Arashi Quincy Kieboom Esmee Wuijster Karina Meijer Marieke J H A Kruip Frank W G Leebeek Marjon H Cnossen OPTI ‐CLOT Study Group Source Type: research

Acquired hemophilia following COVID-19 vaccination: Case report and review of literature
CONCLUSIONS: The diagnosis of AHA with a relapse of bullous pemphigoid was made. The patient was treated with recombinant activated factor VII, emicizumab, rituximab, and methylprednisolone. There were no further bleeding events. However, the patient deteriorated because of sepsis and died on the fifteenth day of admission.CONCLUSION: Vaccines may trigger autoimmune events such as AHA. However, proof of causality is not possible and in this case the relapse of bullous pemphigoid before vaccination challenges this even more.PMID:36176309 | PMC:PMC9459413 | DOI:10.1002/rth2.12785 (Source: Thrombosis and Haemostasis)
Source: Thrombosis and Haemostasis - September 30, 2022 Category: Hematology Authors: Michiel Happaerts Thomas Vanassche Source Type: research